Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
In a ranking of cities by safety that was prepared by The Economist newspaper in 2021, Moscow was ranked 38th with a score of 62.5 points. The general level of crime is low. More than 170,000 surveillance cameras in Moscow are connected to a facial recognition system. The authorities approved of a two-month experiment with automatic, real-time recognition of faces, gender, and age of people; so these authorities deployed the system around the entire city. A video surveillance network integrates video cameras in 95% of the city's apartment buildings; on the grounds and inside buildings of schools and kindergartens; and in MCC stations, stadiums, public transit stops, bus stations, parks, and underground passages. Moscow's emergency numbers match those in all other regions of Russia:
== Research and career == Franz became an assistant professor at Duke University in 2003. She is an Associate member of the Duke Cancer Institute. In 2005, Franz was awarded an National Science Foundation CAREER Award. She was made a Sloan Research Fellow in 2008 and promoted to professor in 2015. Franz has investigated the use of cellular metals in antimicrobial resistance. For example, by disrupting the amount of iron in a cell it is possible to withhold an essential pathogen, limiting the growth of microbes. On the other hand, copper can be used to control the growth of microbes, and immune cells appear to move copper to kill pathogens. At the same time, pathogens try to use copper to enhance their resistance and likelihood of survival. Franz attempts to use copper in the same way as biological systems to target antimicrobial agents. She has looked at iron and copper as ionophores; which are important in the virulence of Cryptococcus neoformans. Franz also works on anti-cancer prochelators; molecules that do not have much affinity for metal ions, but can be triggered until they undergo a chemical conversion. Cancer cells have different metallomes than normal cells. For example, prostate cancer results in the overexpression of copper trafficking proteins, causing a high level of copper. She looks to target these copper ions by creating prochelators that become activated in the microenvironment of cancer.
== Research == Research has identified at least one other possible marker that may appear earlier and exclusively during pregnancy. For example, early pregnancy factor (EPF) can be detected in blood within 48 hours of fertilization, rather than after implantation. However, its reliable use as a pregnancy test remains unclear as studies have shown its presence in physiological situations besides pregnancy, and its application to humans remains limited.
Sources: en.wikipedia.org
=== Ortho rearrangement === The “1,5 ” hydrogen shift cause transfer of two γ- hydrogen to two radical sites on two different unsaturated atoms. The same requirements for The “1,5 ” hydrogen shift occur between proper substituents in the ortho positions of the aromatic rings. The same requirements for McLafferty rearrangement apply to ortho rearrangement except for the strong α,β carbon-carbon double bond. Such rearrangement initiates charge-site reaction, resulting in the formation of an odd electron ion and a small neutral molecule ( water, or HCl and so on). This reaction can be utilized to differentiate ortho from para and meta isomersMcLafferty rearrangement apply to double-hydrogen rearrangement. This reaction is observed for three unsaturated functional groups, namely thioesters, esters and amides.
==== Elimination ==== Tizanidine is eliminated 60% in urine and 20% in feces. Its elimination half-life is approximately 2.5 hours. The inactive metabolites of tizanidine have half-lives of 20 to 40 hours.
=== Infectious diseases and public health === A 2023 study published in Vaccine assessed the risk of COVID-19 breakthrough infection and hospitalization among individuals with comorbidities using data from U.S. health-system records, including those from Truveta-affiliated systems. A 2023 study in Frontiers in Public Health evaluated racial inequalities in COVID-19 treatment and in-hospital length of stay in the United States over time, using data derived from large health-system datasets including those affiliated with Truveta. A 2025 study published in the American Journal of Preventive Medicine analyzed trends in syphilis incidence among U.S. adults from January 2017 to October 2024 using Truveta data. Another 2025 study in Sexually Transmitted Diseases assessed the need for creating ICD-10 codes to improve monitoring of doxycycline postexposure prophylaxis prescriptions in the United States.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.